Stock Research for CYTX

CYTX
Current Price

$0.3231


Latest Update: 2018-02-16 16:00:00

High
$ 0.3231
Low
$ 0.3230
Close
$ 0.3230
Volume
5475
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

CYTX Stock Chart & Research Data

The CYTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTX Due diligence Resources & Stock Charts

The CYTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTX Detailed Price Forecast - CNN Money CNN View CYTX Detailed Summary - Google Finance
Yahoo View CYTX Detailed Summary - Yahoo! Finance Zacks View CYTX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CYTX Trends & Analysis - Trade-Ideas Barrons View CYTX Major Holders - Barrons
NASDAQ View CYTX Call Transcripts - NASDAQ Seeking View CYTX Breaking News & Analysis - Seeking Alpha
Spotlight View CYTX Annual Report - CompanySpotlight.com OTC Report View CYTX OTC Short Report - OTCShortReport.com
TradeKing View CYTX Fundamentals - TradeKing Charts View CYTX SEC Filings - Bar Chart
WSJ View Historical Prices for CYTX - The WSJ Morningstar View Performance/Total Return for CYTX - Morningstar
MarketWatch View the Analyst Estimates for CYTX - MarketWatch CNBC View the Earnings History for CYTX - CNBC
StockMarketWatch View the CYTX Earnings - StockMarketWatch MacroAxis View CYTX Buy or Sell Recommendations - MacroAxis
Bullish View the CYTX Bullish Patterns - American Bulls Short Pains View CYTX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CYTX Stock Mentions - StockTwits PennyStocks View CYTX Stock Mentions - PennyStockTweets
Twitter View CYTX Stock Mentions - Twitter Invest Hub View CYTX Investment Forum News - Investor Hub
Yahoo View CYTX Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTX Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTX - SECform4.com Insider Cow View Insider Transactions for CYTX - Insider Cow
CNBC View CYTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTX - OTC Markets
Yahoo View Insider Transactions for CYTX - Yahoo! Finance NASDAQ View Institutional Holdings for CYTX - NASDAQ


Stock Charts

FinViz View CYTX Stock Insight & Charts - FinViz.com StockCharts View CYTX Investment Charts - StockCharts.com
BarChart View CYTX Stock Overview & Charts - BarChart Trading View View CYTX User Generated Charts - Trading View


Latest Financial News for CYTX

Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress
Posted on Thursday February 15, 2018

SAN DIEGO, Feb. 15, 2018-- Cytori Therapeutics, Inc. today presented data from the U.S. 88 patient, 19 center, randomized, double blind, placebo-controlled STAR clinical trial of Cytori Cell Therapy™ for ...


Cytori Therapeutics Announces Inducement Grants for New Employees
Posted on Friday February 09, 2018

SAN DIEGO, Feb. 09, 2018-- Cytori Therapeutics, Inc., announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on January 25, 2018 to four ...


Enrollment Completed in Randomized Clinical Trial of Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
Posted on Monday January 22, 2018

SAN DIEGO, Jan. 22, 2018-- Cytori Therapeutics, Inc. announces completion of patient enrollment in SCLERADEC II, a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial ...


Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today
Posted on Friday January 05, 2018

Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street's bull of the day today with shares that flew 74%. The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive "interest" signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.


Cytori Therapeutics Announces Inducement Grants for New Employees
GlobeNewswire (press release) - Feb 9, 2018
SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on January 25, 2018 to four (4 ...

Analysts See $-0.07 EPS for Cytori Therapeutics, Inc. (CYTX)
Frisco Fastball - 14 hours ago
Analysts expect Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report $-0.07 EPS on March, 22.They anticipate $0.17 EPS change or 70.83 % from last quarter's $-0.24 EPS.
Cytori Therapeutics (NASDAQ:CYTX) Given a $5.00 Price Target by Maxim Group ... - The Ledger Gazette
Near-Term, Can This Stock Move the Needle: Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Collins Courier

Lookout for Price Target? Cytori Therapeutics, Inc. (CYTX), TransUnion (TRU)
StockNewsJournal - Feb 15, 2018
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.

BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted ...
Reuters - Jan 29, 2018
BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board. Reuters Staff. 1 Min Read.

Enter a stock symbol to view the stock details.